The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 1961, 86: 302-306.
Copyright © 1961 by The American Association of Immunologists, Inc.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rothberg, R.
Right arrow Articles by Talmage, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rothberg, R.
Right arrow Articles by Talmage, D. W.

Circulating Antibody and Anaphylaxis in Mice1

Richard Rothberg and David W. Talmage2

From the Department of Medicine, University of Chicago, Chicago, Illinois

Abstract

Using 1.0 mg BSA in incomplete Freund's adjuvant to sensitize mice, and measuring the antibody response as antigen binding per milliliter of sera with the ammonium sulfate salting out technique, experiments were conducted to provide additional information regarding the relationship of circulating antibody to anaphylaxis and the influence of genetic background on both anaphylaxis and the influence of genetic background on both anaphylaxis and the production of circulating antibody.

Evidence is presented to demonstrate that: a) C57 and DBA mice produced small amounts of circulating anti-BSA, and were resistant to anaphylaxis with BSA; b) CF1 mice produced more anti-BSA, and were highly sensitive to anaphylaxis; c) the severity of anaphylaxis observed in all three strains appeared related to the amount of antibody present; d) anaphylactic shock was not observed in any strain until circulating antibody could be demonstrated; e) a 2-mg immunizing dose of BSA resulted in an earlier antibody response and anaphylaxis in CF1 mice than did a 1.0-mg dose.

Footnotes

1 This work was done in part during tenure of a scholarship from the Allergy Foundation of America and from the support of Grant E-1378 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

2 Present address: University of Colorado Medical Center, Denver 20, Colorado.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1961 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1961 by The American Association of Immunologists, Inc. All rights reserved.